Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 3.845 -0.025 (-0.65%) Streaming Delayed Price Updated: 12:48 PM EDT, May 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Autolus Therapeutics Plc ADR < Previous 1 2 3 Next > Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates May 17, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress May 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call May 13, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High November 20, 2023 Via Investor Brand Network Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO April 24, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 April 23, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia April 02, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Changes to its Board of Directors April 01, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates March 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site March 12, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Blood Cancer Journal March 11, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 February 29, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Nature Communications February 22, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Pricing of Underwritten Offering February 08, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in ACS Chemical Biology January 23, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) January 22, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors January 10, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Changes to its Board of Directors December 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 December 09, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL) November 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023 November 15, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces participation in upcoming conferences November 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations November 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus October 17, 2023 From Autolus Therapeutics plc Via GlobeNewswire Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 October 11, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 October 11, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood September 05, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress August 03, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer July 19, 2023 From Autolus Therapeutics plc Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.